Indonesia resumes the usage of the temporarily suspended batch of the Oxford–AstraZeneca COVID-19 vaccine after tests conducted by the Food and Drug Authority showed that there is no relation between the quality of vaccine batch number CTMAV547 and the death of a young man earlier in the month.
Indonesia resumes the usage of temporarily suspended batch of the Oxford–AstraZeneca COVID-19 vaccine after the Food and Drug Authority concluded in a test results that there are no relation between the quality of vaccine batch number CTMAV547 with the post-immunization event reported.
Indonesia resumes the usage of thetemporarily suspended batch of the Oxford–AstraZeneca COVID-19 vaccine after testsconductedbythe Food and Drug Authority showed that there is no relation between the quality of vaccine batch number CTMAV547 andthedeath ofayoungman earlierin themonth.